About this trial
There are very few data in the literature on changes in inflammatory markers when lidocaine is administered perioperatively in patients with colorectal cancer. In patients undergoing surgery for colon cancer, the aim is to conduct a double-blind placebo-controlled study to determine differences in levels of pro-inflammatory markers, postoperative pain and opioid analgesic consumption in the first two days after surgery, and the time to first postoperative bowel movement. Groups of patients receiving perioperative lidocaine infusion, high dose dexamethasone or placebo will be compared.
Eligibility criteria
Qualifiers
colon cancer of any stage of the disease for which elective laparoscopic colon resection and colonic anastomosis will be performed,
age of patients between 18 and 80 years,
low to moderate risk of anesthesia (ASA up to and including 3),
ability to understand the study and to sign an informed consent to participate in the study
Disqualifiers
patients receiving neoadjuvant chemotherapy,
pregnancy or breastfeeding,
known allergy to lidocaine
cardiac rhythm disturbances (bradycardia < 45 beats/min, complete heart block, use of group III antiarrhythmics),
Trial design
Treatments tested in this trial
- Lidocaine
- Placebo